Type 2 Diabetes
34 articles on Type 2 Diabetes, written by Shotlee and medically reviewed for clinical accuracy.
Mounjaro (Tirzepatide) PBS Listing Fails: Impact on Australian Patients
Eli Lilly Australia has announced that Mounjaro (tirzepatide) will not be listed on the Pharmaceutical Benefits Scheme (PBS) for Type 2 Diabetes, citing unsustainable funding conditions. This decision highlights ongoing challenges in accessing modern GLP-1 and GIP therapies.
6 min read
Genetic Variants May Reduce GLP-1 Diabetes Drug Effectiveness
A new Stanford Medicine study uncovers why GLP-1 receptor agonists may not work as well for some Type 2 diabetes patients: certain genetic variants lead to GLP-1 resistance. Carried by about 10% of the population, these variants result in higher but less effective GLP-1 levels. This could guide faster, personalized treatment switches.
6 min read
Study: Semaglutide Does Not Raise NAION Risk in Obesity, Diabetes
A large study presented in San Diego reveals semaglutide use is not associated with higher risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients with overweight or obesity. In fact, it lowered NAION risk by 64% among those with type 2 diabetes compared to non-GLP-1 therapies. Experts emphasize continued monitoring of blood sugar and blood pressure.
5 min read
Man Wanted for Stealing £12k Mounjaro After Court No-Show
A 27-year-old man from Wigan is being hunted by police after failing to appear in court on charges of stealing over £12,000 worth of Mounjaro weight loss injections from his workplace. The theft highlights the skyrocketing demand for this GLP-1 medication used for type 2 diabetes and appetite control. Understand the case details and what makes Mounjaro so sought after.
4 min read
New Diabetes Drug UBT251 Beats Ozempic in Phase 2 Trial
In a Phase 2 clinical trial in China, Novo Nordisk's experimental drug UBT251 surpassed Ozempic, achieving greater reductions in blood sugar (up to 2.16% HbA1c drop) and body weight (up to 9.8% loss). This marks a potential advancement for type 2 diabetes management. Patients on semaglutide saw 1.77% HbA1c and 4.8% weight reductions, while placebo groups lagged behind.
5 min read
Semaglutide Prices Drop 70-90% in India After Generic Launches by Sun Pharma,...
Semaglutide prices in India have plummeted by up to 90% following the launch of over 15 generic versions just days after patent expiry. Major players like Sun Pharma, Zydus Lifesciences, Dr Reddy's, and Natco are offering affordable options for type 2 diabetes and obesity management. This shift promises greater access to this vital GLP-1 agonist therapy.
6 min read
Safety Signals Matter as Semaglutide Scales in India
Semaglutide's patent expiry in India has flooded the market with affordable generics, dropping prices from over ₹10,000 to as low as ₹1,300 per month. While this opens access for millions with Type 2 diabetes and obesity, experts warn of safety risks from misuse without proper guidance. Discover the implications for patients and the growing market.
5 min read
Eli Lilly's Retatrutide Clears First Late-Stage Diabetes Trial
Eli Lilly announced that its next-generation obesity drug retatrutide met both primary and secondary goals in its first late-stage trial for type 2 diabetes patients. The drug achieved significant A1c reductions of 1.7% to 2% and impressive weight loss of up to 16.8% at 40 weeks. This marks a promising advancement for patients struggling with both blood sugar control and weight management.
5 min read
Zydus, Lupin Partner to Launch Ozempic Rival Semaglutide in India
Zydus Lifesciences and Lupin are teaming up to bring Semaglutide injection to India, positioning it as a rival to Ozempic for type 2 diabetes and chronic weight management. Marketed by Zydus with a user-friendly reusable pen, this GLP-1 therapy offers new options for adults with poor glycemic control or obesity-related conditions. Here's what patients need to know about this launch.
5 min read
Eli Lilly's Employer Connect: Unlocking GLP-1 Demand
Eli Lilly is dominating the GLP-1 market with 25% projected growth in 2026, outpacing Novo Nordisk's decline. Their new Employer Connect platform could unlock massive demand for Zepbound by filling employer coverage gaps. Meanwhile, orforglipron shows superior results over Rybelsus in key trials.
5 min read
Semaglutide Could Cost as Little as $28/Year by End of 2026
Semaglutide, the powerhouse behind Ozempic and Wegovy, might soon become dramatically more affordable. A recent study reveals generic versions could cost as little as $28 per person-year after patents expire in 2026. This could transform access to treatment for obesity and type 2 diabetes globally.
5 min read
What Happens After Stopping GLP-1 Drugs Like Ozempic? UK Study Findings
A new Cambridge study reveals that after stopping GLP-1 drugs like Ozempic and Wegovy, patients regain nearly 60% of lost weight within a year, with appetite returning rapidly. Researchers modeled long-term trends showing about 75% regain over time, emphasizing the need for lifestyle support. This comprehensive guide breaks down the findings and what they mean for patients.
6 min read
Study: GLP-1s Reduce Addiction Risks Beyond Weight Loss
A groundbreaking study in the British Medical Journal reveals that GLP-1 drugs like Ozempic offer benefits far beyond weight loss and diabetes control—they significantly reduce risks of alcohol, tobacco, cannabis, and cocaine abuse. Among 606,434 US veterans with type 2 diabetes, these medications lowered substance abuse risks by up to 20%. Experts caution that while promising, more research is needed.
5 min read
Ozempic May Lower Addiction Risk, New BMJ Study Shows
A groundbreaking BMJ study reveals GLP-1 drugs like Ozempic may reduce the risk of developing substance use disorders by 14% in diabetes patients. Among those with existing addictions, hospital admissions dropped 26%. While promising, these are associations from veteran health records—randomized trials are needed for proof.
5 min read
Abbott Launches Extensior as Second Ozempic Brand in India
Abbott is now marketing Extensior, a second brand of Novo Nordisk's Ozempic, for type 2 diabetes management in India. This partnership comes as the semaglutide patent nears expiry, potentially lowering prices. With proven benefits in HbA1c control, weight loss, and cardiovascular risk reduction, it expands access in a country with over 100 million diabetes cases.
5 min read
Ozempic and Metformin: Similarities After Side Effect Warnings
Ozempic and metformin are both widely used for Type 2 diabetes management, sharing benefits like blood sugar control and potential weight loss effects, but recent side effect warnings highlight their overlaps and differences. While metformin serves 120 million people worldwide as a daily tablet, Ozempic is a weekly injection for adults. Understand why consulting your doctor is essential before switching.
6 min read
Eli Lilly's Orforglipron: More Effective GLP-1 Pill for Weight Loss?
Eli Lilly's investigational GLP-1 pill, orforglipron, demonstrated greater weight loss and blood sugar control than oral semaglutide in a major phase 3 trial for type 2 diabetes. Patients lost 6-8% body weight compared to 4-5%, though with higher GI side effects. This could signal a shift toward more effective oral therapies.
6 min read
Healthy Lifestyle Enhances GLP-1 Therapy's CV Benefits in Type 2 Diabetes
New research reveals that pairing GLP-1 receptor agonists with healthy lifestyle habits significantly lowers heart attack, stroke, and CV death risk in type 2 diabetes patients. Those following 6-8 habits plus GLP-1 therapy saw a 43% reduced MACE risk. This study highlights their complementary roles in heart health.
5 min read
Tirzepatide Adverse Events: Subgroup Differences Explored
A new study in BMC Pharmacology and Toxicology uncovers critical subgroup differences in tirzepatide adverse events, showing higher GI intolerance in elderly patients and varied risks based on comorbidities. These insights highlight the need for tailored dosing in type 2 diabetes and obesity treatment. Understand how to balance benefits and risks effectively.
5 min read
Zydus Launches Affordable Semaglutide Brands in India on Patent Expiry
Zydus Lifesciences is set to launch affordable semaglutide injections in India right on patent expiry, targeting the growing Type 2 diabetes and obesity crisis. With innovative reusable pens under brands like SEMAGLYN, MASHEMA, and ALTERME, the company aims to cut costs and improve patient adherence. This move could transform access to GLP-1 therapy for millions.
6 min read
Ozempic-Like Drugs in India May Drop 50% in Price from March 2026
Semaglutide-based weight-loss drugs like Ozempic and Wegovy are set for a price revolution in India, with generics launching after patent expiry on March 20, 2026, potentially halving costs. Domestic giants like Sun Pharmaceutical and Dr. Reddy's are gearing up to make these GLP-1 therapies more affordable amid rising obesity rates. This shift could transform access to effective treatments for diabetes and weight management.
5 min read
Tirzepatide Activates Brown Fat to Burn Calories, Mouse Study Shows
Tirzepatide doesn't just curb hunger—it may directly rev up fat-burning brown adipose tissue, according to a groundbreaking mouse study. Researchers separated its metabolic effects from simple calorie restriction, uncovering benefits for energy expenditure and blood glucose control. This could pave the way for more effective obesity therapies.
6 min read
Novo Nordisk Slashes Wegovy Prices 50%, Ozempic 35% in 2027
Novo Nordisk is dramatically reducing prices for its blockbuster GLP-1 drugs, slashing Wegovy by 50% and Ozempic by 35% to $675 per month starting in January 2027. This move addresses calls for affordability from patients and payers facing high-deductible plans. Amid fierce competition from Eli Lilly's Mounjaro and Zepbound, these cuts could broaden access to these transformative medications.
5 min read
Sciwind Biosciences $495M Pfizer China Deal for Ecnoglutide GLP-1
Sciwind Biosciences has secured a landmark $495 million commercialization deal with Pfizer China for Ecnoglutide, a next-generation cAMP-biased GLP-1 receptor agonist. Approved for type 2 diabetes in China, it shows 15.1% placebo-adjusted weight loss in trials. This partnership aims to address rising obesity rates amid national health initiatives.
6 min read
GLP-1 Weight-Loss Drug Supplements: Help or Hype?
Weight-loss injections like GLP-1 medications are booming, but concerns about nutrient deficiencies are rising too. A review highlights risks for vitamins A, C, D, E, K and key minerals, sparking 'GLP-1 support' supplements. Expert Jordan Beaumont questions if they're necessary or just hype.
6 min read
Oral GLP-1s Benefit HF Patients: SOUL Trial Subanalysis
A subanalysis of the SOUL trial reveals that once-daily oral semaglutide (Rybelsus) lowers the risk of heart failure hospitalization, urgent visits, or CV death by 22% in patients with HF, diabetes, and ASCVD or CKD. Those with preserved ejection fraction (HFpEF) saw even greater protection at 41%. Experts highlight this as a key option for frail patients avoiding injections.
6 min read
Oral Semaglutide Reduces Heart Failure Risk in Type 2 Diabetes: SOUL Trial
New analysis from the SOUL trial reveals oral semaglutide significantly reduces heart failure risks in type 2 diabetes patients who already have the condition. This benefit is especially notable in HFpEF cases, without compromising safety. Discover the details and implications for managing cardiometabolic disease.
5 min read
CagriSema Superior to Semaglutide for HbA1c, Weight Loss in T2D
New topline data from the REIMAGINE 2 trial reveal CagriSema outperforms semaglutide in HbA1c reduction and weight loss for adults with type 2 diabetes inadequately controlled on metformin. Patients on CagriSema 2.4mg/2.4mg saw a 1.91% point HbA1c drop and 14.2% body weight loss at 68 weeks. This combination of cagrilintide and semaglutide sets a new benchmark in T2D therapy.
6 min read
Rejuva Gene Therapy: One-Shot Fix for GLP-1 Weight Loss?
GLP-1 drugs like Ozempic and Wegovy have revolutionized weight loss, but high dropout rates leave many patients vulnerable. Enter Rejuva: a one-time gene therapy from Fractyl Health aiming for years of benefits without injections. We break down the science, promise, and risks.
4 min read
Novo Nordisk vs Eli Lilly: GLP-1 Drugs Showdown
Novo Nordisk and Eli Lilly dominate the GLP-1 market with powerhouse drugs like Wegovy and Zepbound. But which offers better weight loss results, tolerability, and future potential? This guide breaks down the science, clinical trials, and real-world factors to help you decide.
5 min read
Matt Cooper Defends Ozempic Users: Early Adopter Story
Radio host Matt Cooper reveals his journey as an early Ozempic adopter for type 2 diabetes. He defends users struggling with weight, sharing how the GLP-1 drug curbs appetite and led to gallbladder removal. Learn from his candid experiences on semaglutide benefits and challenges.
2 min read
Novo Nordisk's 'There's Only One Ozempic' Campaign Reunites Stars
Novo Nordisk introduces the 'There's Only One Ozempic' campaign, reuniting comedy duo Justin Long and John Hodgman to spotlight Ozempic's unique FDA-approved benefits for type 2 diabetes. The effort uses humor and education to distinguish genuine Ozempic (semaglutide) from unapproved compounded versions. It encourages vital conversations between patients and healthcare providers.
5 min read
Novo Nordisk Introduces Ozempic in India for Type 2 Diabetes, Prices Aligned to Wegovy
Novo Nordisk has launched Ozempic in India, an injectable semaglutide treatment intended for type 2 diabetes. The company is positioning the drug alongside its obesity medication, Wegovy. Pricing will be similar to Wegovy.
2 min read
GLP-1 Medications Outperform Metformin for Weight Management in Teens with Type 2 Diabetes
Research indicates that GLP-1 therapies offer enhanced weight benefits compared to metformin in adolescents diagnosed with type 2 diabetes. The study highlights comparable glycemic control with GLP-1 drugs but superior weight reduction.
4 min read